This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Adam Feuerstein's Biotech Blog

Adam Feuerstein's Biotech Blog

Adam Feuerstein

Adam Feuerstein investigates the highly-speculative world of biotech stocks, and helps biotech investors avoid losing money.

To participate in Adam's "Biotech Stock Mailbag," please send your questions or comments using this form.

To chat with Adam on Twitter, click here.

Biotech Blog

I give BioMarin a 5% chance of winning approval for drisapersen from the FDA following a negative advisory panel. I might be too generous.
11/25/15 6:49AM
A panel of outside experts convened by the U.S. Food and Drug Administration will spend all day Tuesday reviewing drisapersen, BioMarin's experimental drug for Duchenne muscular dystrophy (DMD).
11/24/15 7:39AM
The last thing the biotech industry needs today is another hit to investor credibility. Clovis isn't helping.
11/21/15 11:30AM
It's almost cruel to see Al Mann being forced back into the CEO role at MannKind, but the company's near-total collapse demands it.
11/20/15 10:36AM
The FDA is highly critical of BioMarin Pharmaceuticals' drisapersen, concluding that efficacy data from three clinical trials do 'not reach the level of substantial evidence' necessary for approval.
11/20/15 8:33AM
BioMarin will almost certainly be halted all day Tuesday, so traders should watch Sarepta Therapeutics and PTC Therapeutics as proxies.
11/19/15 11:42AM
On Nov. 24, a panel of outside experts convened by the U.S. Food and Drug Administration is set to review drisapersen, BioMarin's experimental drug for Duchenne muscular dystrophy.
11/18/15 6:00AM
Clovis Oncology must submit additional clinical data on its targeted lung cancer drug rociletinib to U.S. regulators, delaying the approval review and putting the company further behind rival AstraZeneca.
11/16/15 10:06AM
Biotech columnist Adam Feuerstein answers readers' questions about health care.
11/13/15 9:36AM
MannKind manages to raise a fraction of the money hoped from Israeli investment funds.
11/12/15 3:09PM
I'm often criticized for having nothing positive to say about MannKind, so let the record reflect that I believe the company going to Israel to raise money is smart.
11/10/15 6:58AM
'The chance you would have gotten similar data giving the patients 10 cups of coffee a day instead? Almost 100%,' said Dr. Adam Kline, a researcher who reviewed the data.
11/9/15 8:53AM
Ovarian cancer patients with tumors expressing high levels of a specific protein on their surface respond best to treatment with ImmunoGen's "smart bomb" cancer drug.
11/8/15 12:32PM
New results from a study of Agios' AG-120 in patients with solid tumors were presented at a medical meeting Sunday.
11/8/15 8:01AM
Can Cellectis transform CAR-T from a cool cancer science experiment into a profitable business?
11/5/15 11:21AM
Bluebird Bio is learning differences in the genetic mutation behind beta-thalassemia, a serious, inherited blood disease, is playing a role in how well patients respond to its experimental gene therapy.
11/5/15 8:01AM
Biomarin hasn't started confirmatory trials of DMD drug drisapersen suggested by FDA regulators.
11/2/15 11:40AM
Th purchase of Dyax strengthens Shire's portfolio of drugs treating a rare swelling disorder.
11/2/15 6:56AM
MannKind's signature product contributed only €2 million to Sanofi's diabetes sales in the third quarter.
10/29/15 11:26AM
Lowering its corporate tax burden is a key motivating factor for New York-based Pfizer in any blockbuster deal with Allergan.
10/29/15 8:33AM
Doctors and patients say something must be done to stop Catalyst Pharmaceuticals from emulating the high-priced drug strategies of Valeant and Turing Pharma.
10/29/15 6:20AM
Gilead's hepatitis C drugs are probably the best example of the innovation in medicine we want the biotech industry to strive for when developing new products.
10/28/15 10:09AM
Amgen will market the new drug under the brand name Imlygic. Last Friday, Imlygic also won support from a committee of European drug reviewers.
10/27/15 4:52PM
Merck will conduct an interim analysis before the end of the year of a large, phase III study investigating its cholesterol-lowering pill anacetrapib.
10/27/15 10:01AM

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Real Money
Try it NOW

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums


Chart of I:DJI
DOW 17,719.92 -78.57 -0.44%
S&P 500 2,080.41 -9.70 -0.46%
NASDAQ 5,108.6660 -18.8590 -0.37%
Top Rated Stocks Top Rated Funds Top Rated ETFs